UNSPSC 51384617: Propyphenazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OED8FV75PY, chemically known as 2,3-dimethyl-4-isopropyl-1-phenyl-3h-pyrazolin-5-one but generally known as propyphenazone, which bears US NIH Compound Identifier 3778. European Medicines Agency schedules Propyphenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10125MIG. The term PROPYPHENAZONE is an International Non-Proprietary Name.

UNSPSC 51384617 Propyphenazone, a Commodity code, nominally covers a single analgesic compound, but the recent state and local opportunities tagged under it reflect a much broader pharmaceutical procurement landscape — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. State and local health departments, human services agencies, and cooperative purchasing alliances are the primary buyers, procuring finished pharmaceutical products, medical countermeasures, and pharmacy benefit management services to support public health initiatives, emergency response, and employee health plans. The work ranges from tactical procurement of specific drugs and medical devices for community health building delivery to strategic market-intelligence gathering about pharmacy supply-chain models and long-term vendor qualification for multi-state cooperative agreements.

Issuing bodies include county health departments (Seminole County, Florida), state human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). Recent activity spans Florida, Texas, and the upper Midwest. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription programs with a same-day response window; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products across multiple jurisdictions, with a March 26, 2026 proposal deadline and awards effective July 1, 2026. MMCAP's procurement explicitly mandates compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, FDA approval, and distribution through authorized wholesalers.